X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
http://www.globenewswire.com/news-release/2021/03/08/2188544/0/en/MATEON-S-UPDATE-ON-C001-GLOBAL-STUDY-FOR-OT-101-AGAINST-COVID-19.html
https://www.globenewswire.com/news-release/2020/12/30/2151812/0/en/MATEON-S-GLOBAL-STUDY-FOR-OT-101-TGF-%CE%B2-INHIBITOR-AGAINST-COVID-19-ENROLLS-AND-TREATS-ITS-FIRST-PATIENT.html
https://www.globenewswire.com/news-release/2020/09/16/2094584/0/en/FDA-Granted-Pediatric-Disease-Designation-for-OXi-4503.html
https://www.biospace.com/article/releases/mateon-and-asili-research-alliance-enter-into-partnership-for-the-development-of-artemisinin-against-covid-19/
https://www.globenewswire.com/news-release/2020/07/13/2061115/0/en/Mateon-Therapeutics-to-fund-observational-studies-of-Artemisinin-in-developing-countries.html
https://www.globenewswire.com/news-release/2020/07/09/2059841/0/en/Company-expands-its-management-team-to-accelerate-the-commercialization-and-development-of-OT-101-for-COVID-19.html
https://www.globenewswire.com/news-release/2020/06/24/2052621/0/en/Mateon-is-Selected-by-IBM-Watson-Health-for-the-Use-of-IBM-Clinical-Development-Solution-at-No-Cost-for-Phase-II-Clinical-Trial-of-OT-101-for-COVID-19.html
https://www.globenewswire.com/news-release/2020/06/10/2046197/0/en/Mateon-Announces-Achievement-of-Milestone-Under-Licensing-of-OT-101-IL-2-Combination-to-Autotelic-BIO.html
https://www.biospace.com/article/releases/mateon-provides-update-on-its-r-and-d-effort-against-covid-19/
https://www.biospace.com/article/releases/mateon-announces-the-filing-of-an-ind-with-us-fda-to-evaluate-its-antisense-drug-candidate-ot-101-in-covid-19-patients/
Market Place
Share 
